Previous close | 8.30 |
Open | 8.28 |
Bid | 8.35 x 0 |
Ask | 8.36 x 0 |
Day's range | 8.27 - 8.43 |
52-week range | 6.36 - 15.92 |
Volume | |
Avg. volume | 5,100,325 |
Market cap | 5.057B |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 92.64 |
EPS (TTM) | 0.09 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 03 Jun 2021 |
1y target est | 18.71 |
(Bloomberg) -- Grifols SA shares dropped as investors evaluated a regulatory review of the Spanish bio-science company’s financial reports, which found “relevant deficiencies” but no major accounting mistakes.Most Read from BloombergNY Gears Up to Seize Trump Westchester Assets If Fraud Fine Is UnpaidBaltimore Wants to Sell Hundreds of Vacant Homes for $1 EachWhat Happens If Trump Can’t Post His $454 Million BondChina Scrutinizes PwC Role in $78 Billion Evergrande Fraud CaseYemen’s Houthis Tell
Beleaguered Spanish drugmaker Grifols will not be required to restate its accounts for the years 2021 and 2022, market supervisor CNMV said on Thursday, as its investigation found no significant errors in the amounts it had reported. CNMV also found "no evidence that the financial debt reported by Grifols does not correspond to reality," it said. Since early January, short-sheller Gotham City Research had released three reports repeatedly accusing Grifols of overstating earnings and understating debt in its financial accounts.
Europe's main stock indices were flat on Friday, but notched strong gains over the week that saw record highs from German and French shares, while investors also analysed a U.S. jobs report for clues on the global monetary policy outlook. Technology lost 1.6% after BE Semiconductor slumped 16.1% on a media report that Joint Electron Device Engineering Council lowered certain chip standards which might delay investments into hybrid bonding technology.